Chen Yen-Cheng, Chuang Chia-Hsien, Miao Zhi-Feng, Yip Kwan-Ling, Liu Chung-Jung, Li Ling-Hui, Wu Deng-Chyang, Cheng Tian Lu, Lin Chung-Yen, Wang Jaw-Yuan
Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Front Oncol. 2022 Sep 23;12:955313. doi: 10.3389/fonc.2022.955313. eCollection 2022.
Studies have reported the effects of the gut microbiota on colorectal cancer (CRC) chemotherapy, but few studies have investigated the association between gut microbiota and targeted therapy. This study investigated the role of the gut microbiota in the treatment outcomes of patients with metastatic CRC (mCRC). We enrolled 110 patients with mCRC and treated them with standard cancer therapy. Stool samples were collected before administering a combination of chemotherapy and targeted therapy. Patients who had a progressive disease (PD) or partial response (PR) for at least 12 cycles of therapy were included in the study. We further divided these patients into anti-epidermal growth factor receptor (cetuximab) and anti-vascular endothelial growth factor (bevacizumab) subgroups. The gut microbiota of the PR group and bevacizumab-PR subgroup exhibited significantly higher α-diversity. The β-diversity of bacterial species significantly differed between the bevacizumab-PR and bevacizumab-PD groups ( = 0.029). exhibited the greatest fold change in abundance in the PD group than in the PR group. and species exhibited higher abundance in the PD group. The abundance of was approximately 32 times higher in the PD group than in the PR group. A higher gut microbiota diversity was associated with more favorable treatment outcomes in the patients with mCRC. Bacterial species analysis of stool samples yielded heterogenous results. exhibited the greatest fold change in abundance among all bacterial species in the PD group. This result warrants further investigation especially in a Taiwanese population.
研究报告了肠道微生物群对结直肠癌（CRC）化疗的影响，但很少有研究调查肠道微生物群与靶向治疗之间的关联。本研究调查了肠道微生物群在转移性结直肠癌（mCRC）患者治疗结果中的作用。我们招募了110例mCRC患者，并对他们进行标准癌症治疗。在联合化疗和靶向治疗前采集粪便样本。研究纳入了在至少12个周期治疗后出现疾病进展（PD）或部分缓解（PR）的患者。我们进一步将这些患者分为抗表皮生长因子受体（西妥昔单抗）和抗血管内皮生长因子（贝伐单抗）亚组。PR组和贝伐单抗-PR亚组的肠道微生物群表现出显著更高的α多样性。贝伐单抗-PR组和贝伐单抗-PD组之间细菌种类的β多样性存在显著差异（=0.029）。 在PD组中丰度的变化倍数比PR组中最大。 和 物种在PD组中丰度更高。PD组中 的丰度比PR组中高约32倍。肠道微生物群多样性较高与mCRC患者更有利的治疗结果相关。粪便样本的细菌种类分析产生了异质性结果。 在PD组中所有细菌种类中丰度的变化倍数最大。这一结果值得进一步研究，尤其是在台湾人群中。
